Gene therapy: a market in full revolution
Over the past twenty years, gene therapies – the modification or repair of genes, or the use of genetic material for therapeutic purposes – have transformed medicine. They offer hope to patients with rare and previously incurable diseases by introducing DNA or RNA directly into cells.
Current vectors’ limitations: a barrier to broad adoption
Breakthrough genetic therapies rely on three core elements:
- a genetic message,
- a delivery system – also called “carrier” or “vector”,
- the target cells.
Today’s vectors have significant limitations: lipid nanoparticles (LNPs) lack precise targeting and mostly accumulate in the liver, while viral vectors (VVs) have limited loading capacity and can be immunogenic. At the same time, loading drugs into extracellular vesicles (EVs) requires complex procedures.
The breakthrough: EVis NanoVectors
EVis Bioscience, a spin-off of ETH Zurich incorporated in June 2024, is developing EVis NanoVector, a platform that enables the easy, rapid introduction of RNA into EVs.
EVis NanoVector enables therapies to:
• Load small and large RNAs into EVs
• Achieve precise targeting in specific tissues/organs
• Maintain low toxicity
• Can be produced easily and on a large scale
With two international patents, this approach paves the way for the next generation of RNA-based gene therapies.
Rapid production and industrial scalability
The EVis NanoVector platform, soon to be designated RUO (Research Use Only), is under further development to be ready for large-scale production. CRO and research laboratories will purchase the platform to use EVis’ technology. The platform opens up applications beyond RNA therapies, including CRISPR. EVis will also provide dedicated services and facilities for research laboratories focused on RNA delivery using EVs.
A strategic market with strong growth potential
The global reagent market is estimated at $979 million in 2024 and is expected to reach $1.92 billion by 2030 (CAGR 8.8%). The exosome segment, where EVis places its platform, is valued at $177.4 million in 2024 and is expected to reach approximately $794 million by 2026 (CAGR 28.7%). In parallel, EVis aims to penetrate the gene therapy market. The global gene therapy market size was estimated at $5.54 billion in 2023 and is projected to reach $18.20 billion by 2030, growing at a CAGR of 18.88% from 2024 to 2030.
The EVis NanoVector Platform – coming to market mid-2026
EVis will market its platforms within 8-9 months, generating recurring revenue starting in 2026. At the same time, a licensing program will allow pharmaceutical companies to leverage technology to develop targeted therapies, generating additional revenue streams. Additionally, EVis is developing new therapies to treat rare genetic conditions.
A proven team ready to deliver
Under the scientific guidance of Professor Montanari (CTO) and the direction of Tommaso Caselli (Director, CCO) and the support of Gianfranco Vento (CFO), the team combines scientific, business and financial expertise to achieve its goals. Hiring a CEO with deep experience in the pharmaceutical industry will further strengthen EVis’s ability to achieve and ensure successful commercialization, and to conclude the preclinical phase with obtaining the IND/CTA.
Fundraising: seize the opportunity
EVis is raising 700,000 € – of which 84% are already guaranteed – to develop and commercialize early-stage platforms, expand its therapeutic pipeline, associated services, and licensing initiatives. This is an opportunity to invest in a differentiated biotech company with recurring revenues, strategic licensing, and a promising therapeutic pipeline in a rapidly growing market, with 25x ROI potential by 2028.
Invest today and shape the gene therapy of tomorrow
EVis Bioscience combines a unique patented technology, scheduled for launch in 8-9 months, with an experienced team. Investing today means participating in the global democratization of gene therapies and seizing the potential of a high-value-added and rapidly growing market.
